Form 4: Hologic Director Exercises, Sells Stock Options

Hologic Director Christiana Stamoulis exercised and immediately sold 7,402 shares of common stock under a pre-arranged 10b5-1 trading plan.

Summary

• Christiana Stamoulis, a Director of Hologic Inc. (HOLX), engaged in a pre-planned transaction on October 20, 2025.
• Ms. Stamoulis exercised non-qualified stock options to acquire 7,402 shares of common stock at an exercise price of $36.04 per share.
• Concurrently, she sold all 7,402 newly acquired shares of common stock at a price of $73.07 per share.
• The transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on February 19, 2025, designed to exercise and sell stock options expiring on March 2, 2026.
• Following these transactions, Ms. Stamoulis's direct beneficial ownership of Hologic common stock stands at 47,336 shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the director profited, the transaction was pre-planned under a 10b5-1 plan, which typically mitigates any strong positive or negative signals associated with insider buying or selling.

Positives

• The director realized a significant profit from the exercise and immediate sale of options, with shares acquired at $36.04 and sold at $73.07.
• The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a structured and pre-scheduled event rather than a reaction to new, non-public information.

Negatives

• The director's direct beneficial ownership of common stock decreased by 7,402 shares following the sale, from 54,738 to 47,336 shares.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This is a routine insider transaction disclosure for a director of a publicly traded company in the healthcare technology sector. Such transactions, especially when executed under a 10b5-1 plan, are common and typically do not reflect new insights into the company's operational performance or market position.

Stakeholder Impact

• Shareholders: The transaction is a routine insider disclosure and does not provide new fundamental information that would significantly impact shareholders. The director's beneficial ownership decreased slightly.

Key Dates

Recommendation

This Form 4 filing details a routine, pre-scheduled insider transaction (exercise and sell) by a director under a 10b5-1 plan. Such transactions are generally not indicative of new fundamental information about the company's prospects and therefore do not warrant a change in investment recommendation. The transaction itself does not provide a basis for a 'buy' or 'sell' signal for a seasoned investor.

Keywords

Hologic, HOLX, Form 4, Insider Transaction, Stock Options, Director, Share Sale, 10b5-1 Plan